Search results
Results From The WOW.Com Content Network
On the cost side, Pfizer achieved $4 billion in savings and announced an additional $1.5 billion in margin improvements. In R&D, leadership changed for the first time in 15 years,
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024. ... Revenue from COVID products fell to $12.5 billion in 2023, down 78% from the $57 billion of peak in 2022. Analysts expect ...
Pfizer now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior forecast of $2.15 to $2.35. ... Pfizer was disappointed with its 2023 launch of RSV shot ...
Rank Drug Main indication Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban
Pfizer shares were off less than 1% in midday trading. Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared.
The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from it prior forecast of $67 billion to $70 billion. It said the reduction was solely due to lowered ...
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...
Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1. ...